Should We Systematically Screen for the Amyloidogenic V142I Variant?

Competing Interests: Disclosures MGK reports institutional research support from Pfizer, BridgeBio Pharma, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals, consulting/advisory board support from BridgeBio Pharma and Alnylam Pharmaceuticals, and is a member of Alnylam Pharmaceuticals Speaker's Bureau. OAO receives research support from National Institute on Minority Health and Health Disparities (5R01-MD016401) KMA has received an investigator-initiated research grant from Alnylam and consulting fees from Arbor Biotechnologies, Attralus, Intellia, and Prothena. SHS reports research funding through sponsored research agreements to Duke University from Astra Zeneca, Lilly, and Verily and is a coinventor of unlicensed patents held by Duke University. SS receives research support from the National Heart, Lung, and Blood Institute (K23HL161348), Doris Duke Charitable Foundation (#2020061), American Heart Association (#935275), the Mandel Foundation, Duke Heart Center Leadership Council, the Institute for Translational Medicine and Therapeutics, and Foundation for Sarcoidosis Research and has participated in advisory boards for AstraZeneca. All other authors report no relevant disclosures.